Clinical Trial Update: Gemtuzumab Ozogamicin and High-Dose Cytarabine in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia [Phase 2]

View source ↗

Summary

Phase 2 trial evaluating the combination of gemtuzumab ozogamicin with high-dose cytarabine in relapsed or refractory acute myeloid leukemia has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Acute Myeloid Leukemia

Drugs mentioned

• CYTARABINE (CYTARABINE)
• Gemtuzumab ozogamicin (gemtuzumab ozogamicin)

Snippet

Sponsor: Alliance for Clinical Trials in Oncology | Conditions: Leukemia | Phase 2 | Status: COMPLETED